CytomX Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(17,368) | $31,869 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Amortization of intangible assets | 146 | 146 |
| Depreciation and amortization | 1,230 | 1,622 |
| Impairment loss on machinery and equipment | 402 | 106 |
| Accretion of discounts on short-term investments | (2,206) | (5,311) |
| Stock-based compensation expense | 6,302 | 7,668 |
| Non-cash lease expense | 4,483 | 4,084 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | 1,090 | 329 |
| Prepaid expenses and other assets | (1,242) | 1,433 |
| Accounts payable | 221 | (297) |
| Accrued liabilities and other long-term liabilities | (3,049) | (9,628) |
| Deferred revenue | (65,596) | (118,252) |
| Net cash used in operating activities | $(75,587) | $(86,231) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (220) | (310) |
| Purchases of short term investments | (192,524) | (155,490) |
| Maturities of short term investments | 133,000 | 255,500 |
| Net cash provided by (used in) investing activities | $(59,744) | $99,700 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of pre-funded warrants and warrants, net of issuance cost | — | — |
| Proceeds from issuance of common stock, net of issuance cost | 109,635 | 6,909 |
| Proceeds from employee stock purchase plan and exercise of stock options | 811 | 613 |
| Net cash provided by financing activities | $110,446 | $7,522 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (24,885) | 20,991 |
| Cash, cash equivalents and restricted cash, beginning of year | 39,079 | 18,088 |
| Cash, cash equivalents and restricted cash, end of year | $14,194 | $39,079 |
| Supplemental disclosures of noncash investing items: | ||
| Purchases of property and equipment in accounts payable and accrued liabilities | $— | $8 |
| Supplemental disclosures of noncash financing items: | ||
| Deemed dividend on warrants | $3,002 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.